Gastroenterology and Liver

Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, remains an area of intense research focus due to its complex pathogenesis and chronic nature. This session will delve into the latest developments in understanding genetic, immunological, and environmental factors that contribute to IBD onset and progression. Researchers will present findings on molecular pathways, cytokine networks, and immune cell interactions that influence disease activity. The track will also cover advancements in diagnostic modalities, including endoscopic imaging, molecular biomarkers, and non-invasive monitoring techniques, providing clinicians with tools to improve early diagnosis and disease stratification. Participants can engage with emerging therapeutic approaches, including biologics, small molecule inhibitors, and novel immunomodulators that target specific disease pathways.

The session further explores strategies for optimizing patient management, including personalized treatment plans based on genetic and phenotypic profiles. Longitudinal studies, real-world data, and clinical trial outcomes will be discussed to understand long-term disease management, flare prediction, and risk stratification. Topics such as nutritional therapy, psychosocial support, and surgical interventions will be integrated to provide a comprehensive view of patient-centered care. By participating in this track, attendees will gain an in-depth understanding of current challenges, innovative treatment options, and research opportunities in IBD, enabling them to contribute to improved outcomes and future advancements in the field.

Endoscopy remains a cornerstone in the diagnosis and management of gastrointestinal disorders, and recent technological advances have revolutionized this field. This track will cover cutting-edge developments in diagnostic and therapeutic endoscopy, including high-definition imaging, narrow-band imaging, confocal laser endomicroscopy, and endoscopic submucosal dissection. Experts will present data on the efficacy and safety of these modalities in detecting early neoplastic lesions, polyps, and inflammatory conditions. The session will also examine innovations in endoscopic interventions for complex GI pathologies, such as hemostasis, stricture dilation, and minimally invasive resections, highlighting improvements in patient outcomes and procedural efficiency. Case-based presentations will illustrate practical applications and procedural challenges, providing attendees with actionable insights to enhance clinical practice.

Furthermore, this track emphasizes integrating artificial intelligence, machine learning, and computer-aided detection into endoscopy to improve diagnostic accuracy and workflow efficiency. Participants will explore the role of AI in real-time lesion detection, characterization, and risk stratification, as well as its potential to reduce interobserver variability. Discussion will include training and credentialing strategies for clinicians adopting these technologies, as well as considerations for patient safety and cost-effectiveness. Overall, this session provides a comprehensive platform for sharing research, innovation, and practical experience in advanced GI endoscopy, fostering collaboration and knowledge exchange among gastroenterologists, surgeons, and allied healthcare professionals.

Minimally invasive gastrointestinal surgery has transformed patient care by reducing recovery times, minimizing complications, and improving surgical precision. This session focuses on laparoscopic, robotic-assisted, and hybrid surgical techniques for the management of various GI disorders, including colorectal cancer, gastric malignancies, and complex hepatobiliary diseases. Experts will present evidence-based data from clinical trials, meta-analyses, and real-world practice, showcasing procedural innovations and outcomes. Discussions will highlight strategies for optimizing surgical planning, patient selection, and perioperative care to maximize efficacy and safety. Attendees will have the opportunity to examine technical nuances, intraoperative imaging, and enhanced recovery protocols, ensuring comprehensive exposure to the evolving landscape of minimally invasive surgery.

The track also addresses training and skill development for surgeons, including simulation-based learning, mentorship models, and certification programs that ensure procedural competency. Special attention will be given to emerging technologies such as 3D visualization, augmented reality-assisted surgery, and robotic instrumentation, which enhance precision and patient safety. Postoperative management, complication prevention, and long-term outcomes will be discussed in detail, providing a holistic view of patient care. By participating in this session, surgeons, gastroenterologists, and researchers will gain valuable insights into the latest techniques, evidence, and innovations in minimally invasive gastrointestinal surgery, facilitating improved patient outcomes and fostering the adoption of best practices globally.

Gastrointestinal oncology represents a rapidly evolving field with ongoing advancements in early detection, molecular profiling, and targeted therapies. This session will cover the latest developments in colorectal, gastric, esophageal, pancreatic, and hepatobiliary cancers, focusing on precision medicine and individualized treatment strategies. Researchers will present findings on biomarkers, genetic mutations, tumor microenvironment interactions, and immunotherapy applications that are shaping current and future cancer management. The track will also explore screening programs, risk stratification, and minimally invasive interventions that improve early detection rates and clinical outcomes, emphasizing evidence-based approaches.

Additionally, this session will highlight multidisciplinary collaboration in managing GI cancers, including integration of surgery, chemotherapy, radiotherapy, and emerging immunotherapeutic agents. Case studies, clinical trials, and translational research will be presented to provide a comprehensive understanding of disease mechanisms and treatment responses. Participants will also examine patient-centered approaches, survivorship care, and strategies to manage adverse effects and improve quality of life. Overall, this track aims to advance knowledge, encourage research submissions, and foster collaboration among oncologists, gastroenterologists, surgeons, and allied healthcare professionals engaged in gastrointestinal cancer care.

Chronic and acute liver diseases, including hepatitis, cirrhosis, and acute liver failure, continue to pose global health challenges. This track will explore contemporary diagnostic tools, therapeutic strategies, and patient management approaches for both chronic and acute presentations. Topics include early detection of liver injury, monitoring disease progression, and optimizing pharmacological interventions to prevent complications such as hepatic encephalopathy, portal hypertension, and variceal bleeding. Clinical trials and real-world studies will be shared to inform evidence-based care, offering participants actionable insights to enhance patient outcomes.

The session also emphasizes integrated multidisciplinary management involving hepatologists, surgeons, nutritionists, and critical care specialists. Innovations in supportive care, including advanced monitoring, liver support devices, and regenerative therapies, will be discussed. Attendees will gain insight into emerging therapies targeting specific liver pathologies, as well as strategies for patient stratification and personalized treatment planning. By presenting and engaging in this track, participants can contribute to advancing liver disease research while improving clinical practice standards globally.

NAFLD and NASH have emerged as leading causes of chronic liver disease worldwide, driven by metabolic syndrome, obesity, and lifestyle factors. This session focuses on the pathophysiology, diagnostic approaches, and therapeutic strategies for these conditions. Researchers will present findings on imaging modalities, non-invasive biomarkers, and histopathological evaluations to facilitate early diagnosis and disease staging. The track will highlight lifestyle interventions, pharmacological therapies, and emerging agents targeting fibrosis, inflammation, and metabolic dysregulation, providing attendees with a comprehensive overview of evidence-based management.

In addition, this track will explore precision medicine approaches to NAFLD and NASH, including genetic profiling, risk stratification, and individualized treatment planning. Clinical trials, real-world data, and innovative combination therapies will be discussed to enhance understanding of treatment efficacy and long-term outcomes. Participants will also engage in discussions on public health strategies to mitigate disease burden, including preventive measures, dietary interventions, and patient education. This session aims to foster collaboration, encourage research submissions, and provide actionable insights into one of the most pressing liver health challenges globally.

Pediatric gastroenterology and hepatology addresses the unique gastrointestinal and liver health challenges of neonates, children, and adolescents. This session focuses on congenital, metabolic, and acquired disorders, including biliary atresia, pediatric IBD, liver enzyme abnormalities, and genetic liver diseases. Advances in diagnostics, including non-invasive imaging, genetic testing, and biomarker identification, will be presented to improve early detection and intervention. The track also explores therapeutic strategies ranging from dietary interventions and pharmacological management to surgical procedures and liver transplantation in pediatric populations.

Additionally, this session emphasizes multidisciplinary care and long-term follow-up, addressing growth, nutrition, psychosocial health, and developmental outcomes. Case studies, clinical trials, and translational research will highlight innovative approaches to pediatric care, including stem cell therapies, immunomodulatory agents, and precision medicine applications. Participants will gain insights into optimizing management strategies for pediatric patients, advancing research in this specialized field, and improving clinical outcomes. The session encourages submissions of novel research, case reports, and innovative treatment strategies in pediatric gastroenterology and hepatology.

Aging populations face unique gastrointestinal and liver-related challenges, necessitating specialized care approaches. This track focuses on age-related GI disorders, including motility issues, malabsorption, and functional GI syndromes, as well as liver conditions such as cirrhosis, NAFLD, and hepatocellular carcinoma. The session will explore diagnostic innovations, including non-invasive imaging, biomarker monitoring, and risk stratification models tailored for older adults. Evidence-based management strategies, including pharmacological, nutritional, and procedural interventions, will be highlighted to optimize patient outcomes.

Furthermore, this track addresses the complexities of polypharmacy, comorbidities, and frailty in geriatric patients, emphasizing the importance of individualized treatment plans. Participants will engage with clinical case studies, research findings, and guidelines designed to improve care delivery and quality of life. Preventive strategies, patient-centered approaches, and multidisciplinary collaboration will be discussed, ensuring comprehensive management of elderly patients with gastrointestinal and liver disorders. This session encourages research submissions focusing on innovative approaches, clinical trials, and outcomes in the geriatric population.

The gut microbiome plays a pivotal role in gastrointestinal and liver health, influencing immunity, metabolism, and disease pathogenesis. This session explores the latest research on microbiota composition, function, and interactions with the host in conditions such as IBD, NAFLD, obesity, and gastrointestinal cancers. Participants will gain insights into the therapeutic potential of microbiome modulation through probiotics, prebiotics, fecal microbiota transplantation, and diet-based interventions. Studies examining microbiome-based biomarkers for diagnosis, prognosis, and treatment response will also be presented, fostering innovation and translational research.

In addition, this track emphasizes personalized approaches to microbiome therapy, integrating genomic, metabolomic, and immunological profiling to optimize patient outcomes. Clinical trials, animal models, and case studies will highlight emerging strategies to harness the gut microbiome for disease prevention and treatment. Discussions will also include safety, regulatory considerations, and ethical implications of microbiome-based interventions. Attendees will leave the session equipped with cutting-edge knowledge, practical applications, and research opportunities in this rapidly evolving field, making it highly relevant for both clinicians and researchers.

Liver transplantation remains the definitive treatment for end-stage liver disease, acute liver failure, and certain liver cancers. This session will explore the latest advancements in surgical techniques, organ preservation methods, and immunosuppressive protocols that optimize graft survival and patient outcomes. Experts will present research on living donor transplantation, split-liver techniques, and marginal donor utilization, highlighting strategies to expand the donor pool while minimizing post-operative complications. Discussions will include perioperative management, infection prevention, and risk stratification, providing attendees with practical insights to enhance clinical practice and patient care.

In addition, this track will emphasize emerging technologies and future directions in liver transplantation, including regenerative medicine, bioengineered grafts, and xenotransplantation. Novel immunomodulatory therapies, personalized approaches to rejection prevention, and long-term monitoring strategies will be explored. Case studies, clinical trial data, and international best practices will be shared, offering a comprehensive overview of innovations shaping the field. This session is ideal for hepatologists, transplant surgeons, researchers, and allied healthcare professionals seeking to stay at the forefront of liver transplantation research and clinical management.

Regenerative medicine is transforming gastroenterology and hepatology by offering novel therapeutic options for conditions previously considered irreversible. This session focuses on the application of stem cell therapy, gene editing, and tissue engineering in liver and gastrointestinal disorders. Participants will explore preclinical and clinical studies demonstrating the potential of regenerative approaches to restore tissue function, reduce fibrosis, and promote organ repair. Advances in cellular therapy, biomaterials, and organoid models will be discussed, providing insights into the translation of experimental research into clinical practice.

The track also emphasizes personalized regenerative strategies, highlighting how patient-specific therapies can optimize outcomes and minimize complications. Ethical considerations, regulatory frameworks, and safety challenges associated with regenerative interventions will be addressed. Attendees will engage in discussions on combining regenerative medicine with conventional treatments, evaluating clinical efficacy, and designing research studies that accelerate innovation. This session is intended for researchers, clinicians, and healthcare professionals who wish to contribute to the evolving field of regenerative gastroenterology and hepatology.

Hepatocellular carcinoma (HCC) and other primary liver tumors present significant challenges due to late diagnosis and complex treatment decisions. This track will cover advancements in imaging, biomarker identification, and early detection strategies that improve prognosis and patient survival. Cutting-edge therapies, including surgical resection, locoregional interventions, systemic therapies, and immunotherapy, will be explored in depth. Participants will gain insight into multidisciplinary approaches that integrate hepatology, oncology, radiology, and surgery to deliver optimal care for liver tumor patients.

Additionally, the session highlights emerging research in precision oncology, molecular profiling, and personalized treatment planning for liver tumors. Case studies and clinical trial findings will illustrate real-world applications and challenges in managing HCC and rare liver malignancies. Discussions will include monitoring treatment response, managing complications, and improving patient quality of life. This track is designed for hepatologists, oncologists, surgeons, and researchers interested in advancing clinical knowledge, sharing research, and improving outcomes for patients with liver tumors.

Cholangiocarcinoma, a rare but aggressive biliary tract malignancy, demands early detection and innovative management strategies. This session will explore molecular mechanisms, genetic mutations, and tumor microenvironment interactions that drive disease progression. Participants will review advancements in diagnostic imaging, biomarker discovery, and histopathological evaluation for improved early detection and risk stratification. Therapeutic innovations, including surgical interventions, targeted therapies, immunotherapy, and combined modality approaches, will be presented to enhance survival and clinical outcomes.

The track also emphasizes collaborative research and multidisciplinary care models in managing cholangiocarcinoma. Case discussions, clinical trials, and translational research findings will be shared to highlight real-world challenges and solutions. Participants will explore future directions, including precision medicine approaches, novel systemic agents, and patient-specific treatment planning. This session provides an ideal platform for researchers, clinicians, and healthcare professionals to exchange knowledge, present their work, and contribute to improving outcomes for cholangiocarcinoma patients.

Endoscopic ultrasound (EUS) has revolutionized gastrointestinal and hepatobiliary diagnostics, enabling high-resolution imaging and minimally invasive interventions. This session will focus on recent advancements in EUS technology, including fine-needle aspiration, elastography, contrast-enhanced imaging, and confocal endomicroscopy. Participants will explore clinical applications in tumor staging, pancreaticobiliary disorders, submucosal lesions, and cystic lesions of the liver and pancreas. Case-based presentations will highlight procedural techniques, complication management, and integration into routine clinical practice.

Moreover, the track will address the evolving role of advanced imaging modalities combined with EUS, including AI-assisted diagnostics, fusion imaging, and three-dimensional reconstructions. Discussions will emphasize diagnostic accuracy, workflow optimization, and training protocols for endoscopists. By attending this session, participants will gain comprehensive insights into cutting-edge imaging techniques, emerging technologies, and research opportunities that advance the field of gastroenterology and hepatology.

Artificial intelligence (AI) and digital health are transforming gastroenterology by enabling more accurate diagnostics, personalized treatment planning, and improved patient monitoring. This session explores AI applications in endoscopy, radiology, predictive analytics, and disease risk stratification. Participants will review machine learning algorithms for polyp detection, cancer screening, and disease progression prediction. Digital health platforms, wearable devices, and telemedicine applications that enhance patient engagement and chronic disease management will also be covered, highlighting innovative approaches to modern GI care.

Additionally, this track emphasizes challenges, opportunities, and ethical considerations in implementing AI-driven solutions. Discussions will include validation of AI tools, regulatory frameworks, data privacy, and integration into clinical workflows. Participants will gain insights into how AI can improve efficiency, reduce diagnostic errors, and enable evidence-based personalized care. This session is designed for clinicians, researchers, technologists, and healthcare administrators aiming to leverage AI and digital innovations in gastroenterology and hepatology.

Precision medicine is reshaping the management of gastrointestinal and liver diseases by tailoring interventions based on genetic, molecular, and phenotypic profiles. This session will explore emerging biomarkers for disease diagnosis, prognosis, and therapeutic monitoring in conditions such as IBD, liver fibrosis, and GI cancers. Participants will learn about novel genomic, transcriptomic, proteomic, and metabolomic approaches that inform individualized treatment decisions. The track also covers strategies for integrating biomarker-driven therapies into clinical practice, enhancing patient outcomes and reducing adverse effects.

In addition, this session emphasizes translational research efforts that bridge laboratory discoveries to patient care. Case studies, clinical trial results, and real-world applications will illustrate the impact of precision medicine on treatment selection, disease monitoring, and long-term outcomes. Participants will gain insights into ongoing research opportunities, emerging technologies, and strategies for implementing biomarker-guided care. This track is ideal for clinicians, researchers, and scientists focused on advancing personalized approaches in gastroenterology and hepatology.

Alcoholic liver disease (ALD) remains a major cause of liver-related morbidity and mortality worldwide. This session will focus on pathophysiology, early detection, and comprehensive management strategies for ALD, including alcoholic hepatitis, steatosis, and cirrhosis. Participants will review advancements in non-invasive diagnostics, imaging, and biomarker-based approaches to assess disease severity and progression. Therapeutic interventions, including pharmacologic treatments, nutritional support, and behavioral therapy, will be presented to improve patient outcomes and reduce complications.

The track also explores multidisciplinary care models, integrating hepatologists, addiction specialists, dietitians, and psychologists to optimize treatment. Novel research in molecular mechanisms, targeted therapies, and regenerative approaches will be discussed to identify potential future interventions. Participants will gain insights into clinical challenges, emerging trends, and strategies for patient engagement, early intervention, and prevention, making this session a comprehensive resource for ALD research and care.

Autoimmune liver disorders, including autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC), present unique diagnostic and therapeutic challenges. This session will explore the immunopathogenesis, genetic predisposition, and clinical features of these conditions. Advances in diagnostic strategies, including serological markers, imaging techniques, and histopathology, will be presented to facilitate early and accurate diagnosis. Treatment approaches, ranging from immunosuppressive therapies to emerging biologics, will be discussed with a focus on optimizing patient outcomes and minimizing adverse effects.

In addition, this track highlights long-term management, monitoring for disease progression, and strategies for managing complications such as cirrhosis and liver failure. Case studies, clinical trial findings, and translational research will provide attendees with practical insights and evidence-based approaches. Discussions on personalized care, patient-centered management, and future research directions will foster collaboration and encourage abstract submissions in this evolving field. This session is designed for hepatologists, immunologists, researchers, and allied healthcare professionals engaged in autoimmune liver disease management.

Viral hepatitis remains a significant global health challenge, with millions affected by hepatitis B, C, D, and E worldwide. This session will focus on advances in diagnostics, antiviral therapies, and strategies for disease elimination. Participants will learn about molecular and serological testing, novel treatment regimens, and the role of public health interventions in controlling viral spread. Special emphasis will be placed on hepatitis B and C, including screening programs, treatment monitoring, and prevention strategies such as vaccination and education campaigns.

The track also explores emerging research in hepatitis pathogenesis, drug resistance, and novel therapeutics. Participants will engage with clinical trial data, real-world outcomes, and translational research that informs evidence-based care. Policy, global elimination goals, and strategies to overcome healthcare disparities will be discussed to foster collaborative approaches. This session provides an ideal platform for clinicians, researchers, and public health professionals to present research, exchange knowledge, and contribute to the global effort against viral hepatitis.

Gastrointestinal bleeding is a common yet potentially life-threatening condition, requiring timely diagnosis and intervention. This session focuses on the latest advances in managing both upper and lower GI bleeding, including novel endoscopic hemostatic techniques, interventional radiology approaches, and pharmacological therapies. Participants will explore evidence-based strategies for risk stratification, early detection, and management of bleeding episodes in diverse patient populations. The role of minimally invasive techniques, such as endoscopic clipping, band ligation, and thermal coagulation, will be highlighted, with case studies illustrating real-world clinical decision-making.

Additionally, this track emphasizes innovations in predictive analytics, risk assessment models, and emerging biomarkers to identify patients at high risk for recurrent bleeding. Participants will also review the integration of artificial intelligence in endoscopic detection, therapeutic guidance, and procedural planning. Discussions will include multidisciplinary approaches involving gastroenterologists, surgeons, radiologists, and critical care specialists to optimize patient outcomes. This session provides a platform for clinicians and researchers to share novel findings, clinical experiences, and research proposals aimed at improving management strategies for GI bleeding.

Nutrition and lifestyle play pivotal roles in the prevention and management of gastrointestinal and liver diseases. This session explores the impact of dietary patterns, physical activity, and lifestyle modifications on conditions such as NAFLD, IBD, colorectal cancer, and cirrhosis. Participants will learn about evidence-based nutritional interventions, including specific diets, micronutrient supplementation, and probiotic therapies. The session also addresses the role of lifestyle counseling, behavioral therapy, and patient education in achieving sustainable health outcomes.

The track further emphasizes precision nutrition approaches, integrating genomic, metabolomic, and microbiome data to personalize dietary recommendations. Research on the interplay between nutrition, gut microbiota, and liver metabolism will be presented to highlight novel therapeutic targets. Case studies and clinical trials will showcase effective implementation strategies in diverse populations. Attendees will gain comprehensive insights into how diet and lifestyle interventions can complement pharmacological therapies and enhance overall patient management in gastroenterology and hepatology.

Palliative care is increasingly recognized as essential in managing advanced gastrointestinal and liver diseases, focusing on symptom relief, psychological support, and quality of life. This session will explore strategies for managing pain, fatigue, gastrointestinal symptoms, and hepatic complications in patients with chronic or terminal conditions. Participants will engage with approaches to integrate palliative care into standard clinical practice, including early referral, multidisciplinary collaboration, and patient-centered care planning.

Moreover, this track highlights psychosocial, spiritual, and caregiver support aspects critical to holistic patient management. Research on interventions that improve quality of life, reduce hospitalization, and enhance patient satisfaction will be discussed. Clinical case studies, best practice models, and international guidelines will provide attendees with practical tools to implement palliative strategies effectively. By participating, clinicians and researchers can contribute to advancing care models that prioritize comfort, dignity, and comprehensive support for patients with GI and liver disorders.

Metabolic liver disorders encompass a broad spectrum of genetic and acquired conditions affecting children and adults, including Wilson’s disease, hemochromatosis, and alpha-1 antitrypsin deficiency. This session will explore advances in understanding pathophysiology, early diagnosis, and innovative therapeutic approaches. Participants will gain insights into the role of genetic testing, metabolic profiling, and novel biomarkers in facilitating personalized care. Multidisciplinary strategies, including hepatology, genetics, nutrition, and transplantation, will be emphasized to optimize outcomes for affected patients.

The track also addresses emerging research in disease-modifying therapies, pharmacological interventions, and lifestyle management. Clinical trial data, long-term follow-up studies, and case reports will highlight real-world applications of diagnostic and therapeutic strategies. Participants will discuss challenges in managing pediatric versus adult populations, including growth, development, comorbidities, and quality of life considerations. This session provides a platform for researchers and clinicians to present innovative solutions and collaborate on advancing care for metabolic liver disorders.

Gastrointestinal polyposis syndromes, including familial adenomatous polyposis (FAP) and Peutz-Jeghers syndrome, present significant risks for malignancy and require careful surveillance and management. This session focuses on the genetic, molecular, and clinical aspects of these syndromes, highlighting early detection, risk stratification, and therapeutic interventions. Participants will learn about endoscopic monitoring, surgical management, chemoprevention strategies, and emerging targeted therapies. The track also emphasizes the importance of genetic counseling, family screening, and patient education in reducing disease burden and improving outcomes.

Additionally, this session will explore translational research on novel biomarkers, molecular pathways, and gene-targeted interventions. Case studies and clinical experiences will illustrate challenges in early detection, polyp management, and cancer prevention. Attendees will gain insights into personalized approaches that integrate genetics, endoscopic surveillance, and surgical strategies, making this track an ideal platform for researchers, clinicians, and geneticists to present findings and share expertise.

Pharmacological innovations continue to transform gastroenterology and hepatology, offering new avenues for disease management. This session will focus on recent advances in biologics, small molecule inhibitors, immunotherapies, and combination therapies for conditions such as IBD, liver fibrosis, and GI cancers. Participants will review mechanisms of action, clinical trial results, safety profiles, and therapeutic efficacy of emerging treatments. The track also addresses challenges in drug development, patient selection, and optimizing treatment strategies for diverse populations.

The session further emphasizes translational research and precision medicine approaches in pharmacotherapy. Novel drug delivery systems, repurposed medications, and combination regimens will be discussed for their potential to improve patient outcomes. Participants will also explore regulatory frameworks, cost-effectiveness considerations, and strategies to integrate new therapies into clinical practice. This track provides an interactive platform for clinicians, researchers, and industry professionals to share findings, present ongoing trials, and discuss the future of therapeutics in gastroenterology and hepatology.

Gastrointestinal and liver diseases represent major public health challenges worldwide, with viral hepatitis, NAFLD, GI cancers, and malnutrition contributing to global morbidity and mortality. This session explores epidemiology, prevention strategies, and public health interventions aimed at reducing disease burden. Participants will review global initiatives, screening programs, vaccination strategies, and policy frameworks that address disparities in care. Emphasis will be placed on collaborative approaches to improve healthcare delivery, patient education, and early diagnosis in low-resource settings.

The track also highlights the role of research, surveillance, and data-driven strategies in shaping public health policies. Case studies and international experiences will illustrate successful interventions and lessons learned in combating GI and liver disease at the population level. Participants will engage in discussions on global collaboration, healthcare equity, and the translation of research into actionable public health strategies. This session encourages abstract submissions focused on epidemiology, prevention, policy, and innovative interventions to address pressing global challenges.

Clinical trials and translational research are critical for advancing understanding and treatment of gastrointestinal and liver disorders. This session focuses on design, methodology, and outcomes of recent clinical trials across GI and hepatology specialties. Participants will learn about innovative trial designs, patient recruitment strategies, biomarker utilization, and ethical considerations in human research. The track emphasizes the importance of translating laboratory discoveries into clinical applications that improve patient care.

In addition, the session highlights case studies demonstrating successful bench-to-bedside translation in areas such as liver fibrosis, IBD, GI cancers, and metabolic liver disease. Emerging therapies, precision medicine approaches, and multicenter collaborations will be discussed to illustrate how research informs clinical practice. Attendees will gain insight into regulatory requirements, trial optimization, and strategies for generating high-quality evidence, fostering opportunities for collaboration and future research submissions.

Obesity and related gastrointestinal disorders have become major public health concerns, increasing the prevalence of NAFLD, metabolic syndrome, and GI complications. This session will focus on the role of bariatric surgery, endoscopic interventions, and lifestyle modifications in managing obesity and associated GI conditions. Participants will review surgical techniques, preoperative evaluation, postoperative care, and long-term outcomes, emphasizing evidence-based approaches to improve patient health.

The track also explores the pathophysiology of obesity-related liver and GI disorders, including insulin resistance, inflammatory pathways, and microbiome alterations. Clinical case discussions, research findings, and novel therapeutic approaches will illustrate comprehensive management strategies. Participants will gain insight into patient selection, complication prevention, and multidisciplinary care models. This session is ideal for surgeons, gastroenterologists, researchers, and allied healthcare professionals interested in obesity, metabolic health, and GI disease management.

Rare gastrointestinal and liver disorders present unique diagnostic and therapeutic challenges, often requiring specialized expertise and multidisciplinary care. This session focuses on conditions such as rare metabolic liver diseases, congenital GI anomalies, autoimmune syndromes, and atypical GI cancers. Participants will learn about advances in genetic testing, molecular diagnostics, and targeted therapies that enhance early detection and patient management. Case studies, clinical trial updates, and translational research findings will provide practical insights for managing these complex conditions.

Additionally, the track emphasizes collaborative research networks, patient registries, and international partnerships to improve understanding and treatment of rare disorders. Strategies for optimizing patient care, including personalized medicine approaches, supportive therapies, and innovative interventions, will be discussed. Attendees will gain knowledge to enhance clinical practice, contribute to research efforts, and participate in the global exchange of expertise on rare gastrointestinal and liver conditions.